
  
    
      
        Introduction_NNP
        The_DT use_NN of_IN highly_RB active_JJ antiretroviral_NN therapy_NN (_( HAART_NNP )_) can_MD dramatically_RB prolong_VB the_DT
        life_NN of_IN individuals_NNS infected_VBN by_IN human_JJ immunodeficiency_NN virus_NN 1_CD (_( HIV-_NNP 1_LS )_) [_NN 1_CD ]_NN ,_, but_CC early_JJ hopes_NNS
        for_IN virus_NN eradication_NN have_VBP not_RB been_VBN realized_VBN [_NN 2_CD ]_NN ._. The_DT successful_JJ use_NN of_IN HAART_NNP is_VBZ limited_VBN by_IN
        drug-related_JJ toxicities_NNS ,_, high_JJ costs_NNS ,_, and_CC drug_NN resistance_NN [_NN 3_CD ]_NN ,_, factors_NNS which_WDT have_VBP led_VBN to_TO the_DT
        development_NN of_IN alternative_NN therapeutic_JJ strategies_NNS ,_, including_VBG the_DT use_NN of_IN supervised_JJ ,_, or_CC
        structured_VBD ,_, treatment_NN interruption_NN (_( STI_NNP )_) ._. This_DT approach_NN ,_, involving_VBG recurrent_JJ limited_JJ
        exposure_NN to_TO autologous_JJ virus_NN ,_, has_VBZ not_RB been_VBN successful_JJ in_IN chronic_JJ infection_NN [_NN 4_CD ,_, 5_CD ]_NN ,_, but_CC has_VBZ
        been_VBN shown_VBN to_TO lead_VB to_TO at_IN least_JJS transient_JJ containment_NN of_IN viremia_NN after_IN intervention_NN in_IN the_DT
        acute_JJ phase_NN of_IN infection_NN in_IN humans_NNS and_CC animals_NNS exposed_VBN to_TO AIDS-associated_NNP retroviruses_NNS
        [_NN 6_CD ,_, 7_CD ,_, 8_CD ,_, 9_CD ]_NN ._.
        In_IN the_DT present_JJ study_NN ,_, we_PRP performed_VBD a_DT detailed_VBN longitudinal_NN assessment_NN of_IN the_DT impact_NN of_IN
        early_JJ treatment_NN followed_VBN by_IN STIs_NNP in_IN patients_NNS treated_VBN during_IN acute_JJ or_CC early_JJ HIV-_NNP 1_CD infection_NN ._.
        The_DT main_JJ hypothesis_NNS of_IN the_DT study_NN was_VBD that_IN early_JJ treatment_NN of_IN acute_JJ HIV-_NNP 1_CD infection_NN followed_VBN
        by_IN STI_NNP would_MD lead_VB to_TO immune_JJ boosting_VBG and_CC subsequent_JJ control_NN of_IN viremia_NN without_IN the_DT need_NN for_IN
        drugs_NNS ._. The_DT primary_JJ endpoint_NN was_VBD the_DT time_NN to_TO viral_JJ rebound_NN above_IN 50_CD ,_, 000_CD copies_NNS /_NN ml_NN once_RB or_CC
        above_IN 5_CD ,_, 000_CD copies_NNS for_IN three_CD determinations_NNS separated_VBN by_IN a_DT week_NN each_DT ._. The_DT early_JJ results_NNS of_IN
        this_DT trial_NN were_VBD previously_RB reported_VBN ,_, showing_VBG that_IN five_CD of_IN eight_CD patients_NNS were_VBD able_JJ to_TO
        achieve_VB a_DT plasma_NN viral_JJ load_NN of_IN 500_CD copies_NNS /_NN ml_NN or_CC less_JJR at_IN a_DT median_NN of_IN 6_CD mo_NN off_IN therapy_NN [_NN 6_CD ]_NN ._.
        The_DT current_JJ study_NN investigates_VBZ the_DT frequency_NN and_CC durability_NN of_IN control_NN achieved_VBN with_IN this_DT
        intervention_NN ,_, with_IN follow-up_JJ to_TO a_DT median_NN of_IN 5_CD ._. 3_CD y_NN after_IN infection_NN ,_, and_CC with_IN an_DT increase_NN in_IN
        size_NN of_IN the_DT cohort_NN to_TO 14_CD patients_NNS ._. Our_PRP$ results_NNS indicate_VBP that_IN ,_, although_IN the_DT majority_NN of_IN
        patients_NNS treated_VBN in_IN the_DT acute_JJ phase_NN of_IN infection_NN go_NN on_IN to_TO control_VB HIV-_NNP 1_CD to_TO less_JJR than_IN 5_CD ,_, 000_CD
        RNA_NNP copies_NNS /_NN ml_NN plasma_NN for_IN at_IN least_JJS 6_CD mo_NN off_IN therapy_NN ,_, the_DT ability_NN to_TO contain_VB viremia_NN below_IN
        this_DT level_NN over_IN the_DT long_JJ term_NN is_VBZ maintained_VBN in_IN a_DT minority_NN of_IN patients_NNS ._.
      
      
        Methods_NNP
        
          Objective_NNP
          The_DT hypothesis_NNS of_IN the_DT study_NN was_VBD that_IN early_JJ treatment_NN of_IN acute_JJ HIV-_NNP 1_CD infection_NN would_MD
          confer_VB immunologic_JJ maturation_NN and_CC subsequent_JJ control_NN of_IN HIV-_NNP 1_CD without_IN the_DT need_NN for_IN
          ongoing_JJ drug_NN therapy_NN ._. Alternatively_RB ,_, if_IN a_DT breakthrough_NN of_IN virus_NN replication_NN was_VBD observed_VBN ,_,
          this_DT would_MD provide_VB a_DT boost_NN in_IN HIV-_NNP 1_CD -_: specific_JJ immunity_NN after_IN reinstitution_NN of_IN antiviral_JJ
          therapy_NN ._. The_DT primary_JJ endpoint_NN was_VBD the_DT time_NN to_TO viral_JJ rebound_NN to_TO more_JJR than_IN 50_CD ,_, 000_CD copies_NNS /_NN ml_NN
          or_CC viral_JJ loads_NNS above_IN 5_CD ,_, 000_CD copies_NNS /_NN ml_NN for_IN three_CD determinations_NNS separated_VBN by_IN a_DT week_NN each_DT ._.
          The_DT secondary_JJ objective_NN was_VBD to_TO correlate_VBP immunologic_JJ and_CC virologic_JJ parameters_NNS with_IN any_DT
          observed_VBN effects_NNS including_VBG evolution_NN of_IN HIV-_NNP 1_CD -_: specific_JJ T_NN helper_NN and_CC cytotoxic_JJ T_NN
          lymphocyte_NN responses_NNS ._. The_DT original_JJ study_NN protocol_NN ,_, including_VBG the_DT patient_NN consent_NN form_NN and_CC
          the_DT institutional_JJ review_NN board_NN approval_NN ,_, can_MD be_VB found_VBN in_IN Protocols_NNP S_NNP 1_CD –_NN S_NNP 4_CD ._.
        
        
          Study_NNP Population_NNP
          Fourteen_CD patients_NNS presenting_VBG with_IN acute_JJ or_CC early_JJ HIV-_NNP 1_CD infection_NN were_VBD enrolled_VBN in_IN this_DT
          study_NN between_IN July_NNP 1997_CD and_CC January_NNP 2000_CD (_( Table_NNP 1_LS )_) ._. Acute_NNP HIV-_NNP 1_CD infection_NN was_VBD defined_VBN by_IN
          the_DT presence_NN of_IN HIV-_NNP 1_CD RNA_NNP in_IN the_DT plasma_NN ,_, a_DT negative_JJ or_CC weakly_RB positive_JJ HIV-_NNP 1_CD antibody_NN by_IN
          HIV-_NNP 1_CD /_NN 2_CD ELISA_NNP ,_, and_CC the_DT detection_NN of_IN no_RB more_JJR than_IN three_CD bands_NNS in_IN an_DT HIV-_NNP 1_CD Western_JJ blot_NN ;_:
          early_JJ HIV-_NNP 1_CD infection_NN was_VBD defined_VBN by_IN a_DT positive_JJ ELISA_NNP and_CC confirmation_NN of_IN early_JJ infection_NN
          by_IN either_DT detuned_JJ negative_JJ ELISA_NNP or_CC previously_RB known_VBN negative_JJ ELISA_NNP ._. All_DT participants_NNS in_IN
          the_DT study_NN had_VBD symptoms_NNS compatible_JJ with_IN the_DT acute_JJ retroviral_NN syndrome_NN and_CC were_VBD treated_VBN
          with_IN HAART_NNP (_( one_CD protease_NN inhibitor_NN and_CC two_CD nucleoside_NN reverse_NN transcriptase_NN inhibitors_NNS )_)
          within_IN a_DT median_NN of_IN 19_CD d_SYM (_( range_NN ,_, 9_CD –_NN 33_CD )_) from_IN the_DT onset_NN of_IN symptoms_NNS ._. Study_NN participants_NNS were_VBD
          recruited_VBN from_IN the_DT Massachusetts_NNP General_NNP Hospital_NNP ,_, the_DT Brigham_NNP and_CC Women_NNP 's_POS Hospital_NNP ,_, and_CC
          the_DT Fenway_NNP Community_NNP Heath_NNP Care_NNP Center_NNP in_IN Boston_NNP ._. All_DT individuals_NNS gave_VBD written_VBN informed_VBN
          consent_NN to_TO participate_VB ,_, and_CC the_DT study_NN was_VBD approved_VBN by_IN the_DT respective_JJ institutional_JJ review_NN
          boards_NNS and_CC conducted_VBN in_IN accordance_NN with_IN the_DT human_JJ experimentation_NN guidelines_NNS of_IN the_DT
          Massachusetts_NNP General_NNP Hospital_NNP ._.
          Six_CD of_IN the_DT 14_CD individuals_NNS were_VBD investigated_VBN in_IN an_DT interim_JJ study_NN [_NN 10_CD ]_NN ._. These_DT patients_NNS
          were_VBD AC-_NNP 02_CD (_( AS_NNP 2_CD in_IN [_NN 10_CD ]_NN )_) ,_, AC-_NNP 05_CD (_( AS_NNP 5_LS )_) ,_, AC-_NNP 14_CD (_( AS_NNP 1_LS )_) ,_, AC-_NNP 15_CD (_( AS_NNP 3_LS )_) ,_, AC-_NNP 25_CD (_( AS_NNP 6_CD )_) ,_, and_CC AC-_NNP 46_CD
          (_( AS_NNP 4_LS )_) ._.
        
        
          STIs_NNP
          Entry_NNP criteria_NNS included_VBD treatment_NN with_IN HAART_NNP before_IN or_CC shortly_RB after_IN HIV-_NNP 1_CD
          seroconversion_NN ,_, viral_JJ suppression_NN on_IN HAART_NNP to_TO less_JJR than_IN 400_CD RNA_NNP copies_NNS /_NN ml_NN for_IN 2_CD mo_NN ,_, HIV-_NNP 1_CD
          viral_JJ load_NN at_IN the_DT time_NN of_IN entry_NN into_IN the_DT study_NN of_IN less_JJR than_IN 50_CD RNA_NNP copies_NNS /_NN ml_NN ,_, and_CC lack_NN of_IN
          significant_JJ mutations_NNS conferring_VBG drug_NN resistance_NN [_NN 11_CD ,_, 12_CD ]_NN ._. Lymphocyte_NNP proliferative_JJ
          response_NN to_TO recombinant_JJ HIV-_NNP 1_CD p_NN 24_CD protein_NN had_VBD to_TO exceed_VB a_DT stimulation_NN index_NN of_IN ten_CD before_IN
          treatment_NN discontinuation_NN ,_, and_CC net_JJ counts_NNS per_IN minute_NN had_VBD to_TO be_VB 800_CD or_CC greater_JJR ._. All_DT
          antiretroviral_NN drugs_NNS were_VBD discontinued_VBN simultaneously_RB ._. After_IN a_DT treatment_NN interruption_NN ,_,
          patients_NNS were_VBD seen_VBN at_IN least_JJS once_RB a_DT week_NN for_IN the_DT first_JJ 24_CD wk_NN ,_, and_CC then_RB monthly_JJ ,_, with_IN a_DT
          total_NN of_IN at_IN least_JJS 30_CD visits_NNS for_IN the_DT first_JJ year_NN after_IN cessation_NN of_IN therapy_NN ._. In_IN the_DT second_JJ
          year_NN ,_, visits_NNS continued_VBD monthly_JJ ._. Treatment_NNP was_VBD restarted_VBN if_IN viral_JJ load_NN remained_VBD above_IN
          5_CD ,_, 000_CD RNA_NNP copies_NNS /_NN ml_NN plasma_NN for_IN greater_JJR than_IN three_CD consecutive_JJ weeks_NNS ,_, or_CC was_VBD in_IN excess_NN of_IN
          50_CD ,_, 000_CD copies_NNS /_NN ml_NN on_IN any_DT single_JJ occasion_NN ._.
        
        
          Human_NNP Leukocyte_NNP Antigen_NNP Typing_NNP
          High-_NNP and_CC intermediate-resolution_JJ human_JJ leukocyte_NN antigen_NN class_NN I_PRP typing_VBG was_VBD performed_VBN
          at_IN a_DT commercial_JJ laboratory_NN (_( Dynal_NNP Biotech_NNP ,_, Oxford_NNP ,_, United_NNP Kingdom_NNP )_) by_IN sequence-specific_JJ
          PCR_NNP as_IN described_VBN [_NN 13_CD ]_NN ._.
        
        
          Detection_NNP of_IN GB_NNP Virus_NNP C_NNP RNA_NNP
          GB_NNP virus_NN C_NNP (_( GBV-C_NNP )_) RNA_NNP was_VBD detected_VBN using_VBG a_DT two-step_JJ nested_JJ PCR_NNP amplification_NN reaction_NN
          from_IN whole_JJ plasma_NN RNA_NNP ._. Briefly_NNP ,_, GBV-C_NNP RNA_NNP was_VBD extracted_VBN from_IN plasma_NN using_VBG the_DT Qiagen_NNP
          Viral_NNP RNA_NNP Mini_NNP Kit_NNP (_( Qiagen_NNP ,_, Valencia_NNP ,_, California_NNP ,_, United_NNP States_NNPS )_) according_VBG to_TO the_DT
          manufacturer_NN 's_POS instructions_NNS ._. Extracted_NNP RNA_NNP was_VBD reverse_VB transcribed_JJ using_VBG the_DT Qiagen_NNP
          OneStep_NNP RT-PCR_NNP Kit_NNP and_CC amplified_VBN by_IN nested_JJ PCR_NNP ;_: in_IN both_DT steps_NNS primers_NNS specific_JJ for_IN the_DT 5_CD ′_NN
          UTR_NNP of_IN GBV-C_NNP were_VBD used_VBN ,_, as_IN described_VBN previously_RB [_NN 14_CD ]_NN ._.
        
        
          Chemokine_NNP Receptor_NNP Genotyping_NNP
          In_IN order_NN to_TO analyze_VB the_DT chemokine_NN receptor_NN (_( CCR_NNP )_) 5_CD Δ_NN 32_CD deletion_NN polymorphism_NN ,_, the_DT
          region_NN spanning_VBG the_DT 32_CD -_: nt_RB deletion_NN was_VBD amplified_VBN by_IN PCR_NNP ,_, and_CC the_DT two_CD alleles_NNS were_VBD
          separated_VBN by_IN gel_NN electrophoresis_NNS [_NN 15_CD ]_NN ._. The_DT CCR_NNP 2_CD –_NN 64_CD I_PRP polymorphism_NN was_VBD detected_VBN by_IN
          PCR–restriction_NNP fragment_NN length_NN polymorphism_NN analysis_NN as_IN described_VBN previously_RB [_NN 16_CD ]_NN ._.
        
        
          Synthetic_NNP HIV-_NNP 1_CD Peptides_NNP
          We_PRP synthesized_JJ 410_CD synthetic_JJ peptides_NNS 15_CD –_NN 20_CD amino_JJ acids_NNS long_RB at_IN the_DT Massachusetts_NNP
          General_NNP Hospital_NNP Peptide_NNP Core_NNP Facility_NNP on_IN an_DT automated_VBN peptide_NN synthesizer_NN using_VBG Fmoc_NNP
          technology_NN ,_, as_IN described_VBN [_NN 17_CD ]_NN ._. Peptides_NNP overlapped_JJ by_IN 10_CD amino_JJ acids_NNS and_CC spanned_VBD the_DT
          entire_JJ HIV-_NNP 1_CD clade_NN B_NNP 2001_CD consensus_NN sequence_NN ._.
        
        
          ELISPOT_NNP Assays_NNP
          ELISPOT_NNP assays_NNS were_VBD carried_VBN out_IN as_IN described_VBN previously_RB [_NN 18_CD ]_NN ._. Peripheral_NNP blood_NN
          mononuclear_NN cells_NNS (_( PBMCs_NNP )_) were_VBD incubated_JJ overnight_JJ at_IN 50_CD ,_, 000_CD to_TO 100_CD ,_, 000_CD cells_NNS /_NN well_RB in_IN
          96_CD -_: well_RB polyvinylidene_NN plates_NNS that_WDT had_VBD been_VBN precoated_JJ with_IN 0_CD ._. 5_CD μg_NN /_NN ml_NN anti-human_JJ
          interferon-γ_JJ monoclonal_NN antibody_NN (_( Mabtech_NNP ,_, Stockholm_NNP ,_, Sweden_NNP )_) ._. The_DT final_JJ concentration_NN of_IN
          the_DT peptide_NN per_IN well_RB was_VBD 14_CD μg_NN /_NN ml_NN ._. The_DT numbers_NNS of_IN spots_NNS per_IN well_RB were_VBD counted_VBN using_VBG an_DT
          automated_VBN ELISPOT_NNP plate_NN reader_NN (_( AID_NNP EliSpot_NNP reader_NN system_NN ,_, Autoimmune_NNP Diagnostika_NNP ,_,
          Strassberg_NNP ,_, Germany_NNP )_) ._. A_DT response_NN was_VBD considered_VBN positive_JJ if_IN there_EX were_VBD more_JJR than_IN 50_CD
          spot-forming_JJ cells_NNS (_( SFCs_NNP )_) /_NN 10_CD
          6_CD PBMCs_NNP and_CC if_IN the_DT well_NN had_VBN at_IN least_JJS three_CD times_NNS the_DT mean_JJ number_NN of_IN
          SFCs_NNP in_IN the_DT three_CD control_NN wells_NNS ._. The_DT dependence_NN of_IN responses_NNS on_IN CD_NNP 8_CD +_NN T_NN cells_NNS was_VBD
          determined_VBN by_IN measuring_VBG the_DT depletion_NN of_IN CD_NNP 4_CD +_NN T_NN cells_NNS using_VBG the_DT Minimacs_NNP cell_NN depletion_NN
          system_NN (_( Miltenyi_NNP Biotec_NNP ,_, Bergisch-_NNP Gladbach_NNP ,_, Germany_NNP )_) ._. When_WRB HIV-_NNP 1_CD -_: specific_JJ CD_NNP 8_CD +_NN T_NN cell_NN
          responses_NNS were_VBD detected_VBN against_IN adjacent_JJ peptides_NNS ,_, and_CC therefore_RB might_MD represent_VB
          targeting_VBG of_IN the_DT overlap_VB region_NN ,_, responses_NNS to_TO the_DT weaker_JJR peptide_NN were_VBD excluded_VBN for_IN
          calculations_NNS of_IN magnitude_NN and_CC breadth_NN ,_, as_RB previously_RB described_VBD [_NN 19_CD ]_NN ._.
        
        
          Proliferation_NNP Assays_NNP
          Freshly_NNP isolated_VBD PBMCs_NNP (_( 10_CD
          5_CD cells_NNS )_) were_VBD incubated_JJ with_IN baculovirus-derived_JJ recombinant_JJ p_NN 24_CD
          protein_NN (_( Protein_NNP Sciences_NNPS ,_, Meriden_NNP ,_, Connecticut_NNP ,_, United_NNP States_NNPS )_) at_IN 5_CD μg_NN /_NN ml_NN for_IN 6_CD d_SYM and_CC
          then_RB pulsed_JJ with_IN 
          3_CD H_NNP thymidine_NN at_IN 1_CD ._. 0_CD μCi_NN for_IN 6_CD h_NN before_IN harvesting_NN as_RB previously_RB
          described_VBD [_NN 20_CD ]_NN ._. A_DT stimulation_NN index_NN of_IN five_CD or_CC greater_JJR was_VBD considered_VBN significant_JJ ._.
        
        
          Statistical_NNP Analysis_NNP
          Time_NNP to_TO failure_NN during_IN the_DT different_JJ treatment_NN interruptions_NNS was_VBD assessed_VBN by_IN
          Kaplan-_NNP Meier_NNP analysis_NN ._. Patients_NNS who_WP were_VBD still_RB controlling_VBG viremia_NN at_IN the_DT time_NN of_IN last_JJ
          visit_NN ,_, who_WP failed_VBD because_IN they_PRP restarted_VBD therapy_NN without_IN meeting_VBG the_DT criteria_NNS of_IN
          virologic_JJ failure_NN ,_, or_CC who_WP were_VBD lost_VBN in_IN follow-up_JJ were_VBD included_VBN in_IN the_DT analyses_NNS ,_, but_CC the_DT
          data_NNS were_VBD censored_VBN at_IN the_DT last_JJ evaluable_JJ time_NN point_NN ._. Equality_NNP of_IN survival_NN distributions_NNS
          for_IN the_DT first_JJ and_CC second_JJ treatment_NN discontinuations_NNS was_VBD evaluated_VBN using_VBG the_DT Wilcoxon_NNP
          matched-pairs_JJ signed-ranks_JJ test_NN ._. CD_NNP 4_CD +_NN T_NN cell_NN losses_NNS were_VBD calculated_VBN on_IN regression_NN lines_NNS
          based_VBN on_IN least_JJS squares_NNS fit_VBP ._. A_DT Cox_NNP proportional_JJ hazards_NNS regression_NN model_NN was_VBD used_VBN for_IN the_DT
          analysis_NN of_IN continuous_JJ variables_NNS such_JJ as_IN days_NNS following_VBG onset_NN of_IN symptoms_NNS ,_, CD_NNP 4_CD +_NN T_NN cell_NN
          count_NN ,_, HIV_NNP viral_JJ load_NN ,_, and_CC time_NN to_TO rebound_NN of_IN viremia_NN ,_, as_RB well_RB as_IN for_IN the_DT estimation_NN of_IN
          hazard_NN ratios_NNS for_IN the_DT categorical_JJ variables_NNS of_IN ELISA_NNP ,_, Western_NNP Blot_NNP ,_, coreceptor_NN
          polymorphism_NN ,_, and_CC GBV-C_NNP status_NN ._. Statistical_NNP analyses_NNS of_IN CD_NNP 8_CD +_NN and_CC CD_NNP 4_CD +_NN T_NN cell_NN responses_NNS
          were_VBD based_VBN on_IN a_DT Student_NNP 's_POS 
          t_NN test_NN ,_, a_DT multiparametric_JJ ANOVA_NNP test_NN ,_, a_DT Wilcoxon_NNP matched-pairs_JJ
          signed-ranks_JJ test_NN ,_, or_CC a_DT Mann-_NNP Whitney_NNP 
          U_NNP test_NN ,_, as_IN indicated_VBN ._. 
          p_NN -_: values_NNS lower_JJR than_IN 0_CD ._. 05_CD were_VBD considered_VBN to_TO indicate_VB statistical_JJ
          significance_NN ,_, and_CC all_DT reported_VBN 
          p_NN -_: values_NNS are_VBP two-sided_JJ ._. Statistical_NNP analysis_NN and_CC graphical_JJ
          presentation_NN were_VBD performed_VBN using_VBG SPSS_NNP ,_, SAS_NNP ,_, and_CC Prism_NNP software_NN packages_NNS ._.
        
      
      
        Results_NNS
        
          Longitudinal_NNP Assessment_NNP of_IN Control_NNP of_IN Viremia_NNP following_VBG Treated_NNP Acute_NNP or_CC Early_RB
          Infection_NNP
          Fourteen_CD patients_NNS identified_VBN at_IN the_DT time_NN of_IN acute_JJ or_CC early_JJ infection_NN (_( Table_NNP 1_CD ;_: Figure_NN
          1_LS )_) were_VBD entered_VBN into_IN this_DT protocol_NN ,_, and_CC they_PRP were_VBD followed_VBN for_IN a_DT median_NN of_IN 5_CD ._. 3_CD y_NN from_IN the_DT
          time_NN of_IN infection_NN (_( range_NN ,_, 494_CD –_NN 2_CD ,_, 475_CD d_SYM )_) ._. Patients_NNS underwent_VBD successive_JJ treatment_NN
          interruptions_NNS after_IN an_DT initial_JJ treatment_NN period_NN of_IN at_IN least_JJS 8_CD mo_NN (_( median_JJ ,_, 508_CD d_SYM ;_: range_NN ,_,
          245_CD –_NN 1_CD ,_, 096_CD d_SYM )_) and_CC were_VBD required_VBN to_TO restart_VB therapy_NN when_WRB viral_JJ load_NN exceeded_VBD 50_CD ,_, 000_CD RNA_NNP
          copies_NNS /_NN ml_NN plasma_NN on_IN a_DT single_JJ occasion_NN ,_, or_CC 5_CD ,_, 000_CD copies_NNS /_NN ml_NN for_IN three_CD consecutive_JJ weeks_NNS ._.
          For_IN purposes_NNS of_IN analysis_NN ,_, patients_NNS who_WP dropped_VBD out_IN of_IN the_DT study_NN or_CC who_WP reinitiated_JJ
          therapy_NN without_IN meeting_NN criteria_NNS were_VBD considered_VBN to_TO have_VB lost_VBN the_DT ability_NN to_TO contain_VB
          viremia_NN ._.
          Using_VBG these_DT criteria_NNS for_IN reinitiation_NN of_IN therapy_NN and_CC to_TO define_VB failure_NN ,_, 11_CD of_IN 14_CD
          patients_NNS (_( 79_CD %_NN )_) were_VBD able_JJ to_TO achieve_VB virologic_JJ control_NN to_TO less_JJR than_IN 5_CD ,_, 000_CD RNA_NNP copies_NNS /_NN ml_NN
          plasma_NN for_IN at_IN least_JJS 90_CD d_SYM after_IN one_CD ,_, two_CD ,_, or_CC three_CD treatment_NN interruptions_NNS (_( Table_NNP 2_LS )_) ._. The_DT
          period_NN of_IN longest_JJS containment_NN was_VBD after_IN one_CD interruption_NN for_IN five_CD patients_NNS ,_, after_IN two_CD
          interruptions_NNS for_IN eight_CD patients_NNS ,_, and_CC after_IN three_CD interruptions_NNS for_IN one_CD patient_NN (_( Table_NNP
          3_LS )_) ._.
          Once_RB control_NN was_VBD achieved_VBN ,_, the_DT majority_NN of_IN the_DT patients_NNS experienced_VBD a_DT subsequent_JJ rise_NN
          in_IN viremia_NN ._. The_DT median_JJ time_NN between_IN cessation_NN of_IN therapy_NN and_CC rebound_NN of_IN viremia_NN (_( having_VBG a_DT
          viral_JJ load_NN greater_JJR than_IN 50_CD copies_NNS /_NN ml_NN )_) was_VBD 17_CD d_SYM (_( range_NN ,_, 7_CD –_NN 169_CD d_SYM )_) ._.
          Six_CD of_IN 14_CD patients_NNS (_( 43_CD %_NN )_) achieved_VBD a_DT period_NN of_IN control_NN after_IN stopping_VBG therapy_NN for_IN 1_CD y_NN ,_,
          but_CC only_RB three_CD of_IN 14_CD (_( 21_CD %_NN )_) were_VBD able_JJ to_TO control_VB viremia_NN off_IN therapy_NN at_IN less_JJR than_IN 5_CD ,_, 000_CD
          RNA_NNP copies_NNS /_NN ml_NN plasma_NN for_IN more_JJR than_IN 2_CD y_NN ._. Duration_NNP of_IN viremia_NN control_NN during_IN successive_JJ
          treatment_NN interruptions_NNS was_VBD highly_RB variable_JJ ,_, and_CC there_EX was_VBD no_DT increase_NN in_IN the_DT
          sustainability_NN of_IN viral_JJ containment_NN during_IN successive_JJ STI_NNP cycles_NNS ._. The_DT three_CD patients_NNS
          achieving_VBG control_NN of_IN viremia_NN for_IN more_JJR than_IN 2_CD y_NN did_VBD so_RB during_IN the_DT first_JJ (_( AC-_NNP 10_CD )_) ,_, the_DT
          second_JJ (_( AC-_NNP 02_CD )_) ,_, and_CC the_DT third_JJ (_( AC-_NNP 14_CD )_) treatment_NN interruption_NN ,_, respectively_RB (_( Figure_NN 2_CD A_DT )_) ._. A_DT
          paired_VBN comparison_NN (_( Wilcoxon_NNP matched-pairs_JJ signed-ranks_JJ test_NN )_) showed_VBD no_DT significant_JJ
          difference_NN in_IN the_DT length_NN of_IN viremia_NN control_NN with_IN subsequent_JJ treatment_NN interruptions_NNS ._.
          Although_IN patients_NNS experienced_VBD rebound_NN viremia_NN with_IN discontinuation_NN of_IN therapy_NN ,_, none_NN of_IN
          the_DT patients_NNS experienced_VBD recurrence_NN of_IN symptoms_NNS associated_VBN with_IN acute_JJ HIV-_NNP 1_CD
          infection_NN ._.
          These_DT data_NNS show_VBP that_IN at_IN least_JJS transient_JJ control_NN of_IN viremia_NN to_TO less_JJR than_IN 5_CD ,_, 000_CD RNA_NNP
          copies_NNS /_NN ml_NN plasma_NN was_VBD achieved_VBN in_IN the_DT majority_NN of_IN study_NN participants_NNS during_IN at_IN least_JJS one_CD
          of_IN the_DT treatment_NN interruptions_NNS ,_, but_CC that_IN durable_JJ viral_JJ control_NN in_IN participants_NNS following_VBG
          treated_VBN acute_JJ infection_NN occurred_VBD infrequently_RB ._. Moreover_RB ,_, the_DT data_NNS do_VBP not_RB show_VB a_DT
          consistent_JJ pattern_NN of_IN augmentation_NN of_IN viral_JJ control_NN with_IN sequential_NN treatment_NN
          interruptions_NNS ._.
        
        
          Effect_NN of_IN Treatment_NNP Interruptions_NNP on_IN CD_NNP 4_CD +_NN T_NN Cell_NNP Counts_NNP
          Although_IN viral_JJ load_NN is_VBZ a_DT strong_JJ predictor_NN of_IN disease_NN progression_NN ,_, CD_NNP 4_CD +_NN T_NN cell_NN loss_NN is_VBZ
          an_DT additional_JJ ,_, independent_JJ predictor_NN [_NN 21_CD ]_NN ._. Early_RB treatment_NN of_IN acute_JJ HIV-_NNP 1_CD infection_NN led_VBN
          to_TO normalization_NN of_IN CD_NNP 4_CD +_NN T_NN cell_NN counts_VBZ in_IN most_JJS patients_NNS (_( median_JJ ,_, 753_CD cells_NNS /_NN mm_NN
          3_CD ;_: range_NN ,_, 492_CD –_NN 986_CD )_) ,_, but_CC the_DT effect_NN of_IN treatment_NN interruption_NN was_VBD
          variable_JJ ,_, even_RB in_IN those_DT doing_VBG well_RB ,_, as_IN defined_VBN by_IN sustained_VBN low_JJ viral_JJ loads_NNS ._. Overall_RB ,_, 11_CD
          of_IN 14_CD patients_NNS interrupted_VBN therapy_NN for_IN at_IN least_JJS 12_CD mo_NN ,_, and_CC these_DT individuals_NNS were_VBD
          evaluated_VBN regarding_VBG the_DT effect_NN of_IN treatment_NN interruption_NN on_IN CD_NNP 4_CD +_NN T_NN cell_NN loss_NN (_( Figure_NN 2_CD B_NNP
          and_CC 2_CD C_NNP )_) ._. The_DT rate_NN of_IN change_NN in_IN CD_NNP 4_CD +_NN T_NN cell_NN counts_VBZ during_IN the_DT first_JJ year_NN of_IN the_DT longest_JJS
          period_NN off_IN treatment_NN ranged_VBD from_IN +_NN 157_CD to_TO −_NN 438_CD cells_NNS /_NN mm_NN
          3_CD /_NN y_NN (_( median_JJ ,_, −_NN 192_CD )_) ._. Of_IN the_DT three_CD patients_NNS who_WP did_VBD not_RB meet_VB viral_JJ load_NN
          criteria_NNS for_IN restarting_VBG therapy_NN for_IN more_JJR than_IN 2_CD y_NN ,_, one_CD (_( AC-_NNP 02_CD )_) had_VBD an_DT increasing_VBG CD_NNP 4_CD +_NN T_NN
          cell_NN count_NN of_IN 157_CD cells_NNS /_NN mm_NN
          3_CD /_NN y_NN ,_, one_CD (_( AC-_NNP 10_CD )_) had_VBD a_DT stable_JJ CD_NNP 4_CD +_NN T_NN cell_NN count_NN (_( −_NN 9_CD cells_NNS /_NN mm_NN
          3_CD /_NN y_NN )_) ,_, and_CC one_CD (_( AC-_NNP 14_CD )_) experienced_VBD a_DT decline_NN of_IN 344_CD cells_NNS /_NN mm_NN
          3_CD /_NN y_NN ._. Comparison_NNP with_IN data_NNS from_IN the_DT Multicenter_NNP AIDS_NNP Cohort_NNP Study_NNP
          (_( MACS_NNP )_) showed_VBD that_IN the_DT kinetics_NNS of_IN CD_NNP 4_CD +_NN T_NN cell_NN loss_NN was_VBD faster_RBR (_( Mann-_NNP Whitney_NNP 
          U_NNP test_NN ,_, 
          p_NN =_SYM 0_CD ._. 02_CD )_) than_IN in_IN untreated_JJ patients_NNS with_IN early_JJ chronic_JJ HIV-_NNP 1_CD infection_NN
          (_( average_JJ loss_NN of_IN −_NN 67_CD cells_NNS /_NN mm_NN
          3_CD /_NN y_NN in_IN patients_NNS with_IN a_DT CD_NNP 4_CD +_NN T_NN cell_NN count_NN of_IN more_JJR than_IN 350_CD cells_NNS /_NN mm_NN
          3_CD at_IN baseline_NN )_) ._. However_RB ,_, CD_NNP 4_CD +_NN T_NN cell_NN loss_NN rate_NN was_VBD in_IN the_DT same_JJ range_NN
          as_IN what_WP has_VBZ been_VBN described_VBN after_IN treatment_NN interruption_NN in_IN chronic_JJ HIV-_NNP 1_CD infection_NN
          [_NN 22_CD ,_, 23_CD ]_NN ._. Analysis_NNP of_IN CD_NNP 4_CD +_NN T_NN cell_NN decline_NN during_IN the_DT second_JJ year_NN for_IN the_DT three_CD individuals_NNS
          who_WP controlled_VBD viremia_NN for_IN more_JJR than_IN 2_CD y_NN revealed_VBD similar_JJ trends_NNS in_IN CD_NNP 4_CD +_NN T_NN cell_NN slopes_NNS ,_,
          although_IN they_PRP were_VBD less_RBR steep_JJ :_: AC-_NNP 02_CD ,_, +_NN 88_CD cells_NNS /_NN mm_NN
          3_CD /_NN y_NN ;_: AC-_NNP 10_CD ,_, +_NN 44_CD cells_NNS /_NN mm_NN
          3_CD /_NN y_NN ;_: and_CC AC-_NNP 14_CD ,_, −_NN 110_CD cells_NNS /_NN mm_NN
          3_CD /_NN y_NN ._. When_WRB the_DT first_JJ 3_CD mo_NN off_IN therapy_NN were_VBD excluded_VBN in_IN order_NN to_TO
          minimize_VB the_DT potential_JJ effects_NNS of_IN recent_JJ treatment_NN on_IN CD_NNP 4_CD +_NN T_NN cell_NN number_NN ,_, the_DT rate_NN of_IN
          change_NN in_IN CD_NNP 4_CD +_NN T_NN cell_NN counts_VBZ during_IN the_DT first_JJ year_NN off_IN therapy_NN no_RB longer_RB differed_VBD
          statistically_RB from_IN the_DT MACS_NNP data_NN (_( median_JJ ,_, −_NN 207_CD cell_NN /_NN mm_NN
          3_CD /_NN y_NN ;_: range_NN ,_, +_NN 119_CD to_TO −_NN 699_CD ;_: Mann-_NNP Whitney_NNP 
          U_NNP test_NN ,_, 
          p_NN =_SYM 0_CD ._. 07_CD )_) ._. A_DT possible_JJ reason_NN for_IN steep_JJ CD_NNP 4_CD +_NN T_NN cell_NN slopes_NNS may_MD be_VB high_JJ
          CD_NNP 4_CD +_NN T_NN cell_NN counts_VBZ at_IN time_NN of_IN treatment_NN interruption_NN ._. Comparison_NNP with_IN MACS_NNP data_NNS (_( Figure_NN
          2_CD C_NNP )_) showed_VBD that_IN several_JJ of_IN the_DT study_NN participants_NNS still_RB behaved_VBD as_IN outliers_NNS when_WRB this_DT
          factor_NN was_VBD considered_VBN ._. These_DT results_NNS indicate_VBP that_IN periods_NNS of_IN relative_JJ control_NN of_IN viremia_NN
          were_VBD associated_VBN with_IN declining_VBG CD_NNP 4_CD +_NN T_NN cell_NN counts_VBZ in_IN most_JJS patients_NNS ._.
        
        
          Correlation_NNP of_IN Clinical_NNP and_CC Genetic_NNP Markers_NNP with_IN Duration_NNP of_IN Viremia_NNP Control_NNP
          Although_IN the_DT study_NN was_VBD small_JJ ,_, we_PRP evaluated_VBD clinical_JJ and_CC laboratory_NN parameters_NNS to_TO see_VB
          if_IN any_DT was_VBD predictive_JJ of_IN duration_NN of_IN viral_JJ control_NN ._. Analyses_NNS included_VBD clinical_JJ and_CC
          laboratory_NN parameters_NNS at_IN time_NN of_IN presentation_NN with_IN acute_JJ HIV-_NNP 1_CD infection_NN ,_, genetic_JJ markers_NNS
          associated_VBN with_IN different_JJ rates_NNS of_IN disease_NN progression_NN ,_, and_CC the_DT presence_NN or_CC absence_NN of_IN
          GBV-C_NNP coinfection_NN ._. All_DT patients_NNS presented_VBN with_IN symptomatic_JJ acute_JJ infection_NN ._. Time_NNP between_IN
          onset_NN of_IN symptoms_NNS and_CC institution_NN of_IN therapy_NN did_VBD not_RB affect_VB duration_NN of_IN control_NN following_VBG
          STI_NNP (_( Cox_NNP proportional_JJ hazards_NNS regression_NN model_NN ,_, 
          p_NN >_NN 0_CD ._. 05_CD )_) ._. The_DT individuals_NNS who_WP controlled_VBD viremia_NN for_IN a_DT longer_JJR time_NN
          either_CC during_IN the_DT first_JJ STI_NNP or_CC during_IN any_DT of_IN the_DT treatment_NN interruptions_NNS were_VBD not_RB
          different_JJ from_IN those_DT who_WP experienced_VBD earlier_JJR breakthrough_NN as_IN measured_VBN by_IN ELISA_NNP and_CC
          Western_JJ blot_NN status_NN at_IN initiation_NN of_IN HAART_NNP ,_, coreceptor_NN polymorphisms_NNS (_( CCR_NNP 5_CD delta_NN 32_CD ,_, CCR_NNP 2_CD
          V_NNP 64_CD I_PRP )_) ,_, or_CC the_DT presence_NN or_CC absence_NN of_IN GBV-C_NNP coinfection_NN (_( Cox_NNP proportional_JJ hazards_NNS model_NN ,_, 
          p_NN >_NN 0_CD ._. 05_CD in_IN all_DT comparisons_NNS ;_: data_NNS not_RB shown_VBN )_) ._. The_DT only_JJ parameter_NN
          that_WDT was_VBD predictive_JJ of_IN prolonged_JJ viral_JJ control_NN during_IN the_DT first_JJ treatment_NN interruption_NN
          was_VBD a_DT low_JJ viremia_NN at_IN time_NN of_IN institution_NN of_IN therapy_NN (_(
          p_NN =_SYM 0_CD ._. 01_CD )_) :_: there_EX was_VBD a_DT 2_CD ._. 8_CD -_: fold_VB increase_NN in_IN hazard_NN per_IN order_NN of_IN
          magnitude_NN increase_NN in_IN viral_JJ load_NN ._. This_DT factor_NN was_VBD no_DT longer_RB predictive_JJ when_WRB the_DT period_NN of_IN
          longest_JJS control_NN of_IN viremia_NN was_VBD considered_VBN ._. The_DT time_NN to_TO rebound_NN of_IN viremia_NN (_( >_NN 50_CD
          copies_NNS /_NN ml_NN or_CC >_NN 400_CD copies_NNS /_NN ml_NN )_) did_VBD not_RB correlate_VBP with_IN the_DT duration_NN of_IN viral_JJ control_NN ._.
          Although_IN 11_CD out_IN of_IN 14_CD individuals_NNS achieved_VBN at_IN least_JJS transient_JJ control_NN of_IN viremia_NN ,_, and_CC
          three_CD experienced_VBN prolonged_JJ control_NN ,_, none_NN of_IN these_DT patients_NNS possessed_VBD the_DT HLA_NNP alleles_NNS B_NNP 27_CD
          or_CC B_NNP 57_CD associated_VBN with_IN better_RB disease_NN outcome_NN [_NN 24_CD ,_, 25_CD ]_NN ._.
        
        
          Relationship_NNP of_IN Magnitude_NNP and_CC Breadth_NNP of_IN HIV-_NNP 1_CD -_: Specific_JJ CD_NNP 8_CD +_NN T_NN Cells_NNP to_TO Duration_NNP of_IN
          Viremia_NNP Control_NNP
          To_TO assess_VB the_DT relationship_NN between_IN the_DT clinical_JJ outcome_NN and_CC evolution_NN of_IN
          HIV-_NNP 1_CD -_: specific_JJ CD_NNP 8_CD +_NN T_NN cells_NNS ,_, we_PRP longitudinally_RB analyzed_VBD the_DT breadth_NN and_CC magnitude_NN of_IN CD_NNP 8_CD +_NN
          T_NN cell_NN responses_NNS using_VBG an_DT interferon-γ_JJ ELISPOT_NNP and_CC a_DT panel_NN of_IN 410_CD overlapping_VBG peptides_NNS
          spanning_VBG the_DT entire_JJ HIV-_NNP 1_CD clade_NN B_NNP consensus_NN sequence_NN ._. At_IN the_DT beginning_NN of_IN the_DT first_JJ STI_NNP ,_,
          HIV-_NNP 1_CD -_: specific_JJ CD_NNP 8_CD +_NN T_NN cells_NNS were_VBD weak_JJ (_( median_NN of_IN 590_CD SFCs_NNP /_NN 10_CD
          6_CD PBMCs_NNP )_) (_( Figure_NN 3_CD A_DT )_) and_CC narrowly_RB directed_VBN at_IN a_DT median_NN of_IN two_CD epitopes_NNS
          (_( Figure_NN 3_CD B_NNP )_) ._. CD_NNP 8_CD +_NN T_NN cell_NN responses_NNS increased_VBN significantly_RB (_(
          p_NN <_NN 0_CD ._. 05_CD )_) during_IN the_DT first_JJ off-treatment_JJ period_NN ,_, reaching_VBG a_DT median_JJ
          total_JJ magnitude_NN of_IN 2_CD ,_, 725_CD SFCs_NNP /_NN 10_CD
          6_CD PBMCs_NNP and_CC targeting_VBG a_DT median_NN of_IN eight_CD epitopes_NNS ,_, and_CC then_RB were_VBD
          sustained_VBN when_WRB therapy_NN was_VBD reintroduced_VBN ._. A_DT further_JJ increase_NN in_IN the_DT magnitude_NN and_CC breadth_NN
          of_IN HIV-_NNP 1_CD -_: specific_JJ CD_NNP 8_CD +_NN T_NN cells_NNS was_VBD observed_VBN in_IN the_DT subsequent_JJ off-treatment_JJ periods_NNS ,_,
          although_IN these_DT augmentations_NNS failed_VBD to_TO reach_VB statistical_JJ significance_NN ._. The_DT CD_NNP 8_CD +_NN T_NN
          cell–mediated_JJ immune_JJ responses_NNS emerging_VBG during_IN these_DT consecutive_JJ cycles_NNS of_IN treatment_NN
          interruption_NN were_VBD broadly_RB directed_VBN ,_, targeting_VBG all_DT structural_JJ and_CC most_RBS accessory_JJ and_CC
          regulatory_JJ HIV-_NNP 1_CD gene_NN products_NNS (_( data_NNS not_RB shown_VBN )_) ._. However_RB ,_, the_DT magnitude_NN of_IN HIV-_NNP 1_CD -_: specific_JJ
          CD_NNP 8_CD +_NN T_NN cell_NN responses_NNS at_IN the_DT beginning_NN of_IN the_DT first_JJ (_(
          r_LS =_SYM 0_CD ._. 01_CD ,_, 
          p_NN =_SYM 0_CD ._. 76_CD )_) ,_, second_JJ (_(
          r_LS =_SYM 0_CD ._. 16_CD ,_, 
          p_NN =_SYM 0_CD ._. 54_CD )_) ,_, or_CC third_JJ (_(
          r_LS =_SYM 0_CD ._. 1_CD ,_, 
          p_NN =_SYM 0_CD ._. 55_CD )_) treatment_NN interruptions_NNS was_VBD not_RB predictive_JJ of_IN the_DT time_NN the_DT
          study_NN participants_NNS were_VBD subsequently_RB able_JJ to_TO stay_VB off_RP therapy_NN according_VBG to_TO study_NN
          criteria_NNS ._.
          The_DT periods_NNS off_IN treatment_NN allowed_VBN for_IN assessment_NN of_IN the_DT relationship_NN between_IN exposure_NN
          to_TO virus_NN and_CC evolution_NN of_IN immune_JJ responses_NNS ._. There_EX was_VBD a_DT highly_RB significant_JJ positive_JJ
          association_NN between_IN time_NN until_IN virologic_JJ failure_NN during_IN the_DT first_JJ treatment_NN interruption_NN
          and_CC change_NN in_IN the_DT magnitude_NN of_IN HIV-_NNP 1_CD -_: specific_JJ CD_NNP 8_CD +_NN T_NN cell_NN responses_NNS (_(
          r_LS =_SYM 0_CD ._. 92_CD ,_, 
          p_NN <_NN 0_CD ._. 001_CD )_) (_( Figure_NN 3_CD C_NNP )_) ._. Similarly_RB ,_, the_DT longer_RBR a_DT patient_NN remained_VBD off_IN
          therapy_NN during_IN the_DT second_JJ and_CC third_JJ interruptions_NNS ,_, the_DT greater_JJR the_DT augmentation_NN of_IN the_DT
          total_JJ magnitude_NN of_IN HIV-_NNP 1_CD -_: specific_JJ CD_NNP 8_CD +_NN T_NN cell_NN responses_NNS (_(
          r_LS =_SYM 0_CD ._. 83_CD ,_, 
          p_NN <_NN 0_CD ._. 016_CD ;_: 
          r_LS =_SYM 0_CD ._. 74_CD ,_, 
          p_NN =_SYM 0_CD ._. 05_CD ,_, respectively_RB )_) ._. The_DT increase_NN in_IN CD_NNP 8_CD +_NN T_NN cell_NN epitopes_NNS targeted_VBN
          during_IN the_DT first_JJ treatment_NN interruption_NN was_VBD also_RB linearly_RB correlated_JJ to_TO the_DT duration_NN
          until_IN virological_JJ failure_NN (_(
          r_LS =_SYM 0_CD ._. 81_CD ,_, 
          p_NN <_NN 0_CD ._. 001_CD )_) (_( Figure_NN 3_CD D_NNP )_) ._. However_RB ,_, no_DT significant_JJ relationship_NN was_VBD
          observed_VBN between_IN the_DT augmentation_NN of_IN epitopes_NNS targeted_VBN during_IN the_DT second_JJ and_CC third_JJ
          treatment_NN pauses_VBZ and_CC the_DT time_NN the_DT study_NN participants_NNS were_VBD able_JJ to_TO remain_VB off_RP therapy_NN in_IN
          the_DT respective_JJ treatment_NN interruption_NN ._. These_DT data_NNS suggest_VBP that_IN the_DT duration_NN of_IN a_DT
          treatment_NN interruption_NN ,_, and_CC therefore_RB the_DT duration_NN of_IN exposure_NN to_TO plasma_NN virus_NN ,_,
          correlates_NNS positively_RB with_IN the_DT magnitude_NN and_CC breadth_NN of_IN HIV-_NNP 1_CD -_: specific_JJ CD_NNP 8_CD +_NN T_NN cell_NN
          responses_NNS that_WDT emerge_VBP during_IN off-therapy_JJ time_NN periods_NNS ._. Yet_RB ,_, CD_NNP 8_CD +_NN T_NN cell_NN responses_NNS prior_RB
          to_TO treatment_NN interruptions_NNS were_VBD not_RB significantly_RB predictive_JJ of_IN the_DT duration_NN of_IN time_NN that_IN
          patients_NNS are_VBP able_JJ to_TO spontaneously_RB control_VB HIV-_NNP 1_CD replication_NN ,_, as_IN defined_VBN by_IN the_DT study_NN
          criteria_NNS ._.
        
        
          Relationship_NNP of_IN Magnitude_NNP of_IN Lymphocyte_NNP Proliferative_NNP Responses_NNS to_TO p_NN 24_CD Antigen_NNP to_TO
          Duration_NNP of_IN Viremia_NNP Control_NNP
          We_PRP next_RB analyzed_VBD evolution_NN of_IN lymphoproliferative_JJ responses_NNS to_TO recombinant_JJ HIV-_NNP 1_CD p_NN 24_CD
          Gag_NNP protein_NN in_IN order_NN to_TO assess_VB HIV-_NNP 1_CD -_: specific_JJ CD_NNP 4_CD +_NN T_NN cell_NN function_NN ._. Most_JJS individuals_NNS had_VBD
          no_DT detectable_JJ response_NN at_IN baseline_NN prior_RB to_TO treatment_NN ,_, consistent_JJ with_IN prior_JJ reports_NNS of_IN
          patients_NNS with_IN acute_JJ HIV-_NNP 1_CD infection_NN [_NN 20_CD ]_NN ._. After_IN initiation_NN of_IN therapy_NN ,_, all_DT individuals_NNS
          generated_VBD HIV-_NNP 1_CD -_: specific_JJ lymphoproliferative_JJ responses_NNS (_( Figure_NN 3_CD E_NNP )_) ,_, which_WDT was_VBD a_DT criterion_NN
          for_IN inclusion_NN in_IN the_DT study_NN ._. During_IN treatment_NN interruptions_NNS ,_, there_EX was_VBD a_DT variable_JJ decline_NN
          in_IN magnitude_NN ,_, and_CC comparisons_NNS between_IN responses_NNS on_IN the_DT first_JJ day_NN of_IN treatment_NN
          interruption_NN and_CC last_JJ day_NN off_IN therapy_NN did_VBD not_RB reach_VB statistical_JJ significance_NN (_( first_JJ STI_NNP ,_, 
          p_NN =_SYM 0_CD ._. 72_CD ;_: second_JJ ,_, 
          p_NN =_SYM 0_CD ._. 12_CD ;_: and_CC third_JJ ,_, 
          p_NN =_SYM 0_CD ._. 60_CD ,_, respectively_RB )_) ._. These_DT HIV-_NNP 1_CD -_: specific_JJ CD_NNP 4_CD +_NN T_NN cell_NN responses_NNS
          also_RB tended_VBD to_TO rise_VB with_IN reinitiation_NN of_IN therapy_NN ,_, and_CC some_DT of_IN them_PRP were_VBD very_RB robust_JJ ,_, with_IN
          stimulation_NN indices_NNS over_IN 50_CD detected_VBD in_IN several_JJ individuals_NNS (_( Figure_NN 3_CD E_NNP )_) ._. Similar_JJ to_TO CD_NNP 8_CD +_NN
          T_NN cell_NN responses_NNS ,_, the_DT magnitude_NN of_IN HIV-_NNP 1_CD -_: specific_JJ CD_NNP 4_CD +_NN T_NN helper_NN cell_NN responses_NNS at_IN the_DT
          beginning_NN of_IN the_DT first_JJ (_(
          r_LS =_SYM 0_CD ._. 05_CD ,_, 
          p_NN =_SYM 0_CD ._. 43_CD )_) (_( Figure_NN 3_CD F_NN )_) ,_, second_JJ (_(
          r_LS =_SYM 0_CD ._. 16_CD ,_, 
          p_NN =_SYM 0_CD ._. 54_CD )_) ,_, or_CC third_JJ (_(
          r_LS =_SYM 0_CD ._. 1_CD ,_, 
          p_NN =_SYM 0_CD ._. 55_CD )_) treatment_NN interruption_NN was_VBD not_RB statistically_RB predictive_JJ of_IN
          the_DT time_NN the_DT study_NN participants_NNS were_VBD subsequently_RB able_JJ to_TO stay_VB off_RP therapy_NN according_VBG to_TO
          study_NN criteria_NNS ._.
        
      
      
        Discussion_NNP
        Although_IN early_JJ treatment_NN of_IN acute_JJ HIV-_NNP 1_CD infection_NN followed_VBN by_IN treatment_NN interruptions_NNS
        may_MD enhance_VB control_NN of_IN viremia_NN [_NN 6_CD ,_, 8_CD ]_NN ,_, the_DT durability_NN of_IN this_DT control_NN remains_VBZ unclear_JJ ._. Here_RB
        we_PRP analyzed_VBD the_DT long-term_JJ impact_NN of_IN initiation_NN of_IN antiviral_JJ therapy_NN during_IN acute_JJ HIV-_NNP 1_CD
        infection_NN followed_VBN by_IN STIs_NNP in_IN a_DT cohort_NN of_IN 14_CD patients_NNS ._. Although_IN initial_JJ control_NN of_IN viremia_NN
        to_TO less_JJR than_IN 5_CD ,_, 000_CD RNA_NNP copies_NNS /_NN ml_NN plasma_NN was_VBD achieved_VBN in_IN the_DT majority_NN of_IN the_DT individuals_NNS
        studied_VBN ,_, a_DT gradual_JJ increase_NN in_IN viremia_NN and_CC decline_NN in_IN CD_NNP 4_CD +_NN T_NN cell_NN counts_VBZ was_VBD observed_VBN in_IN
        most_JJS patients_NNS ,_, even_RB after_IN a_DT year_NN or_CC more_JJR of_IN viral_JJ containment_NN ._. Durable_JJ virologic_JJ control_NN
        occurred_VBD infrequently_RB ,_, despite_IN the_DT presence_NN of_IN robust_JJ HIV-_NNP 1_CD -_: specific_JJ CD_NNP 4_CD +_NN and_CC CD_NNP 8_CD +_NN T_NN cell_NN
        responses_NNS detected_VBN by_IN standard_JJ assays_NNS ._. Moreover_RB ,_, even_RB during_IN periods_NNS of_IN successful_JJ control_NN
        of_IN viremia_NN ,_, progressive_JJ loss_NN of_IN CD_NNP 4_CD +_NN T_NN cells_NNS was_VBD frequently_RB observed_VBN ._. These_DT data_NNS indicate_VBP
        that_IN although_IN early_JJ treatment_NN of_IN acute_JJ and_CC early_JJ infection_NN is_VBZ frequently_RB associated_VBN with_IN
        transient_JJ control_NN of_IN viremia_NN after_IN STI_NNP ,_, ongoing_JJ low-level_JJ viral_JJ replication_NN is_VBZ associated_VBN
        with_IN ultimate_JJ virologic_JJ breakthrough_NN in_IN most_JJS patients_NNS ._.
        The_DT standard_JJ immunologic_JJ assays_NNS and_CC virologic_JJ assessments_NNS in_IN this_DT cohort_NN revealed_VBD
        considerable_JJ heterogeneity_NN among_IN the_DT study_NN participants_NNS ,_, and_CC did_VBD not_RB show_VB a_DT consistent_JJ
        pattern_NN in_IN duration_NN of_IN viremia_NN control_NN during_IN successive_JJ treatment_NN interruptions_NNS ._. Eleven_CD of_IN
        14_CD patients_NNS (_( 79_CD %_NN )_) were_VBD able_JJ to_TO maintain_VB a_DT viral_JJ load_NN of_IN less_JJR than_IN 5_CD ,_, 000_CD copies_NNS /_NN ml_NN for_IN at_IN
        least_JJS 90_CD d_SYM ,_, but_CC progressive_JJ loss_NN of_IN control_NN ensued_VBD in_IN the_DT majority_NN of_IN patients_NNS and_CC only_RB
        three_CD patients_NNS (_( 21_CD %_NN )_) were_VBD able_JJ to_TO maintain_VB control_NN for_IN more_JJR than_IN 2_CD y_NN ._. These_DT three_CD patients_NNS
        did_VBD so_RB during_IN the_DT first_JJ (_( AC-_NNP 10_CD )_) ,_, the_DT second_JJ (_( AC-_NNP 02_CD )_) ,_, and_CC the_DT third_JJ (_( AC-_NNP 14_CD )_) STI_NNP ._. Clinical_NNP ,_,
        genetic_JJ ,_, and_CC immunological_JJ parameters_NNS did_VBD not_RB distinguish_VB these_DT three_CD individuals_NNS from_IN the_DT
        other_JJ 11_CD patients_NNS ,_, nor_CC did_VBD they_PRP predict_VB the_DT duration_NN of_IN control_NN following_VBG treatment_NN
        interruption_NN ._. Indeed_RB ,_, the_DT longer_RBR a_DT patient_NN was_VBD off_JJ therapy_NN ,_, the_DT stronger_JJR and_CC more_RBR broadly_RB
        directed_VBD the_DT CD_NNP 8_CD +_NN T_NN cell_NN responses_NNS became_VBD ,_, but_CC these_DT were_VBD still_RB not_RB sufficient_JJ to_TO maintain_VB
        prolonged_JJ control_NN in_IN most_JJS patients_NNS ._. Although_IN three_CD patients_NNS did_VBD not_RB complete_VB the_DT study_NN as_RB
        initially_RB intended_VBN (_( patient_NN AC-_NNP 45_CD withdrew_VBD from_IN the_DT study_NN after_IN viral_JJ breakthrough_NN on_IN the_DT
        first_JJ STI_NNP ,_, AC-_NNP 13_CD restarted_VBN therapy_NN despite_IN a_DT viral_JJ load_NN of_IN less_JJR than_IN 5_CD ,_, 000_CD copies_NNS /_NN ml_NN during_IN
        both_DT the_DT first_JJ and_CC second_JJ STIs_NNP and_CC then_RB withdrew_VBD ,_, and_CC AC-_NNP 05_CD restarted_VBN therapy_NN prematurely_RB
        during_IN the_DT second_JJ STI_NNP but_CC then_RB failed_VBD to_TO control_VB during_IN the_DT third_JJ STI_NNP )_) ,_, the_DT results_NNS are_VBP not_RB
        substantially_RB different_JJ if_IN these_DT three_CD are_VBP censored_VBN rather_RB than_IN considered_VBN to_TO have_VB failed_VBN
        to_TO control_VB ._.
        Loss_NN of_IN viral_JJ control_NN in_IN this_DT cohort_NN occurred_VBD not_RB only_RB in_IN the_DT presence_NN of_IN strong_JJ CD_NNP 8_CD +_NN T_NN
        cell_NN responses_NNS ,_, but_CC in_IN most_JJS cases_NNS also_RB in_IN the_DT presence_NN of_IN virus-specific_JJ CD_NNP 4_CD +_NN T_NN cell_NN
        responses_NNS ,_, although_IN the_DT CD_NNP 4_CD +_NN T_NN cell_NN responses_NNS often_RB declined_VBD during_IN periods_NNS of_IN viremia_NN ._. In_IN
        addition_NN ,_, total_JJ CD_NNP 4_CD +_NN T_NN cell_NN numbers_NNS were_VBD also_RB monitored_VBN and_CC declined_VBN in_IN most_JJS patients_NNS over_IN
        time_NN ,_, including_VBG one_CD of_IN the_DT three_CD patients_NNS who_WP were_VBD able_JJ to_TO maintain_VB low_JJ viral_JJ loads_NNS for_IN at_IN
        least_JJS 2_CD y_NN ._. Mechanisms_NNPS leading_VBG to_TO rapid_JJ CD_NNP 4_CD +_NN T_NN cell_NN loss_NN need_VBP to_TO be_VB further_RBR studied_VBN in_IN
        future_JJ STI_NNP trials_NNS ._. Other_JJ parameters_NNS including_VBG chemokine_NN receptor_NN polymorphisms_NNS [_NN 26_CD ]_NN and_CC
        GBV-C_NNP coinfection_NN [_NN 27_CD ,_, 28_CD ]_NN similarly_RB failed_VBD to_TO explain_VB the_DT different_JJ courses_NNS following_VBG
        treatment_NN interruption_NN ._. The_DT only_JJ parameter_NN found_VBD to_TO be_VB associated_VBN with_IN longer_JJR control_NN of_IN
        viremia_NN during_IN the_DT first_JJ treatment_NN interruption_NN was_VBD a_DT lower_JJR viral_JJ load_NN at_IN time_NN of_IN
        institution_NN of_IN antiviral_JJ therapy_NN ._. Given_VBN the_DT multiplicity_NN of_IN comparisons_NNS made_VBN ,_, the_DT true_JJ
        significance_NN of_IN this_DT finding_VBG is_VBZ uncertain_JJ ._.
        The_DT reasons_NNS for_IN progressive_JJ loss_NN of_IN control_NN despite_IN augmentation_NN of_IN virus-specific_JJ CD_NNP 4_CD +_NN
        and_CC CD_NNP 8_CD +_NN T_NN cell_NN responses_NNS remain_VBP to_TO be_VB defined_VBN ._. In_IN one_CD individual_JJ (_( AC-_NNP 06_CD )_) ,_, HIV-_NNP 1_CD
        superinfection_NN in_IN the_DT setting_NN of_IN strong_JJ and_CC broadly_RB directed_VBN HIV-specific_NNP cellular_JJ immune_JJ
        responses_NNS was_VBD associated_VBN with_IN the_DT loss_NN of_IN viral_JJ control_NN ,_, as_RB previously_RB reported_VBD [_NN 29_CD ]_NN ._. No_DT
        other_JJ cases_NNS of_IN superinfection_NN have_VBP been_VBN identified_VBN in_IN these_DT patients_NNS (_( data_NNS not_RB shown_VBN )_) ._. The_DT
        immunologic_JJ studies_NNS performed_VBN failed_VBD to_TO show_VB an_DT association_NN between_IN increases_NNS in_IN viral_JJ load_NN
        and_CC loss_NN of_IN immune_JJ responses_NNS ,_, but_CC this_DT may_MD be_VB due_JJ to_TO the_DT use_NN of_IN the_DT current_JJ standard_JJ IFN-γ_NNP
        assays_NNS to_TO quantify_VB immune_JJ function_NN ._. Numerous_JJ studies_NNS now_RB indicate_VBP that_IN IFN-γ_NNP production_NN
        alone_RB is_VBZ not_RB associated_VBN with_IN viral_JJ load_NN [_NN 19_CD ,_, 30_CD ,_, 31_CD ]_NN but_CC rather_RB that_IN functional_JJ
        characteristics_NNS of_IN CD_NNP 4_CD +_NN and_CC CD_NNP 8_CD +_NN T_NN cells_NNS may_MD be_VB better_RBR associated_JJ with_IN viral_JJ control_NN
        [_NN 32_CD ,_, 33_CD ,_, 34_CD ,_, 35_CD ]_NN ._. Such_JJ studies_NNS will_MD be_VB important_JJ to_TO pursue_VB ._. In_IN particular_JJ ,_, even_RB a_DT low_JJ level_NN of_IN
        viremia_NN correlates_NNS with_IN a_DT low_JJ or_CC undetectable_JJ frequency_NN of_IN interleukin-_NN 2_CD -_: producing_VBG
        HIV-_NNP 1_CD -_: specific_JJ memory_NN CD_NNP 4_CD +_NN T_NN cells_NNS endowed_VBN with_IN proliferative_JJ capacity_NN in_IN vitro_NN
        [_NN 36_CD ,_, 37_CD ,_, 38_CD ,_, 39_CD ]_NN ,_, thus_RB abrogating_VBG CD_NNP 4_CD +_NN T_NN cell_NN help_NN crucial_JJ to_TO maintain_VB efficacy_NN of_IN CD_NNP 8_CD +_NN T_NN cell_NN
        functions_NNS ._. In_IN an_DT interim_JJ study_NN of_IN a_DT subset_NN of_IN six_CD of_IN the_DT 14_CD patients_NNS presented_VBN here_RB
        (_( patients_NNS AC-_NNP 02_CD ,_, AC-_NNP 05_CD ,_, AC-_NNP 14_CD ,_, AC-_NNP 15_CD ,_, AC-_NNP 25_CD ,_, and_CC AC-_NNP 46_CD )_) ,_, a_DT fully_RB differentiated_JJ effector_NN
        phenotype_NN of_IN HIV-_NNP 1_CD -_: specific_JJ CD_NNP 8_CD +_NN T_NN cells_NNS for_IN selected_VBN epitopes_NNS was_VBD found_VBN to_TO be_VB associated_VBN
        with_IN better_RB control_NN of_IN viremia_NN [_NN 10_CD ]_NN ._. Other_JJ factors_NNS that_WDT may_MD contribute_VB include_VB functional_JJ
        defects_NNS in_IN antigen-specific_JJ cell-mediated_JJ immunity_NN [_NN 35_CD ,_, 37_CD ,_, 40_CD ,_, 41_CD ,_, 42_CD ]_NN ,_, and_CC progressive_JJ immune_JJ
        escape_NN [_NN 43_CD ,_, 44_CD ,_, 45_CD ]_NN ._. HIV-_NNP 1_CD -_: specific_JJ humoral_NN immunity_NN can_MD also_RB affect_VB viral_JJ control_NN after_IN
        treatment_NN interruption_NN [_NN 46_CD ]_NN ,_, and_CC viral_JJ factors_NNS including_VBG viral_JJ fitness_NN [_NN 47_CD ,_, 48_CD ]_NN and_CC
        infection_NN with_IN multiple_JJ viral_JJ variants_NNS [_NN 49_CD ]_NN can_MD influence_VB viral_JJ set_VBN point_NN and_CC the_DT rate_NN of_IN
        disease_NN progression_NN ._. Virus_NNP sequencing_VBG studies_NNS currently_RB in_IN progress_NN in_IN this_DT cohort_NN indicate_VBP
        that_IN viral_JJ breakthrough_NN is_VBZ associated_VBN with_IN sequence_NN changes_NNS within_IN and_CC outside_IN known_VBN CTL_NNP
        epitopes_NNS (_( data_NNS not_RB shown_VBN )_) ._. Full_NNP evaluation_NN of_IN the_DT relationship_NN between_IN immune_JJ escape_NN and_CC
        viral_JJ breakthrough_NN will_MD require_VB extensive_JJ additional_JJ analyses_NNS ,_, including_VBG detailed_JJ analysis_NN
        of_IN responses_NNS to_TO autologous_JJ virus_NN [_NN 50_CD ,_, 51_CD ]_NN ._. Assessing_NNP the_DT changes_NNS in_IN CD_NNP 4_CD +_NN and_CC CD_NNP 8_CD +_NN T_NN cell_NN
        functions_NNS over_IN time_NN as_RB well_RB as_IN viral_JJ evolution_NN under_IN immune_JJ selection_NN pressure_NN will_MD be_VB
        important_JJ to_TO evaluate_VB immune_JJ correlates_NNS in_IN this_DT cohort_NN ._.
        These_DT data_NNS are_VBP important_JJ in_IN light_NN of_IN other_JJ recent_JJ data_NNS on_IN treatment_NN interruption_NN in_IN both_DT
        acute_JJ and_CC chronic_JJ infection_NN ._. In_IN chronic_JJ HIV-_NNP 1_CD infection_NN ,_, STI_NNP studies_NNS showed_VBD only_RB marginal_JJ ,_,
        if_IN any_DT ,_, improvements_NNS of_IN HIV-_NNP 1_CD viremia_NN control_NN following_VBG a_DT number_NN of_IN treatment_NN interruptions_NNS
        cycles_NNS ,_, despite_IN at_IN least_JJS transient_JJ increases_NNS in_IN HIV-_NNP 1_CD -_: specific_JJ CD_NNP 8_CD +_NN and_CC CD_NNP 4_CD +_NN T_NN cell_NN
        responses_NNS [_NN 4_CD ,_, 5_CD ,_, 52_CD ,_, 53_CD ,_, 54_CD ,_, 55_CD ]_NN ._. In_IN the_DT setting_NN of_IN infection_NN with_IN a_DT multidrug-resistant_JJ virus_NN ,_,
        this_DT strategy_NN may_MD even_RB be_VB deleterious_JJ [_NN 56_CD ]_NN ._. Other_JJ studies_NNS of_IN STI_NNP after_IN treated_VBN acute_JJ HIV-_NNP 1_CD
        infection_NN have_VBP shown_VBN limited_JJ benefits_NNS [_NN 9_CD ]_NN ,_, including_VBG recent_JJ trials_NNS such_JJ as_IN the_DT PrimSTOP_NNP
        trial_NN [_NN 57_CD ]_NN and_CC the_DT QUEST_NNP study_NN [_NN 58_CD ]_NN ._. However_RB ,_, little_JJ is_VBZ known_VBN about_IN the_DT relationship_NN
        between_IN scheduling_NN of_IN HAART_NNP and_CC treatment_NN interruptions_NNS and_CC the_DT characteristics_NNS of_IN viral_JJ
        rebound_NN after_IN therapy_NN has_VBZ been_VBN discontinued_VBN ._.
        Although_IN durable_JJ control_NN of_IN viremia_NN was_VBD not_RB achieved_VBN ,_, it_PRP is_VBZ noteworthy_JJ that_IN the_DT majority_NN
        of_IN patients_NNS were_VBD able_JJ to_TO achieve_VB transient_JJ relative_JJ containment_NN of_IN viremia_NN ,_, providing_VBG
        rationale_NN for_IN future_JJ studies_NNS aimed_VBN at_IN further_JJ enhancing_VBG immune_JJ control_NN ._. Early_RB treatment_NN
        alone_RB should_MD still_RB be_VB considered_VBN an_DT important_JJ therapeutic_JJ option_NN ._. Therapeutic_NNP vaccinations_NNS
        administered_VBN after_IN treated_VBN acute_JJ HIV-_NNP 1_CD infection_NN and_CC before_IN cessation_NN of_IN therapy_NN have_VBP given_VBN
        disappointing_JJ results_NNS thus_RB far_RB [_NN 9_CD ]_NN ,_, but_CC the_DT availability_NN of_IN new_JJ and_CC more_RBR potent_JJ immunogens_NNS
        requires_VBZ reassessment_NN of_IN this_DT approach_NN ._. Indeed_RB ,_, the_DT ability_NN to_TO enhance_VB CD_NNP 4_CD +_NN T_NN helper_NN cell_NN
        responses_NNS in_IN the_DT chronic_JJ phase_NN of_IN infection_NN has_VBZ been_VBN demonstrated_VBN [_NN 59_CD ]_NN ,_, but_CC whether_IN this_DT
        will_MD enhance_VB CD_NNP 8_CD +_NN T_NN cell_NN function_NN requires_VBZ additional_JJ studies_NNS ._. Some_DT promising_JJ results_NNS have_VBP
        been_VBN obtained_VBN using_VBG immunomodulatory_NN drugs_NNS ,_, including_VBG cyclosporine_NN [_NN 60_CD ]_NN and_CC hydroxyurea_NN
        [_NN 61_CD ]_NN ,_, in_IN combination_NN with_IN antiviral_JJ therapy_NN ,_, presumably_RB because_IN of_IN the_DT limitation_NN of_IN T_NN cell_NN
        activation_NN ._. Administration_NNP of_IN granulocyte-macrophage_JJ colony-stimulating_JJ factor_NN blunted_VBD the_DT
        viral_JJ rebound_NN following_VBG interruption_NN of_IN HAART_NNP ,_, and_CC largely_RB prevented_VBD a_DT decrease_NN of_IN CD_NNP 4_CD +_NN T_NN
        cell_NN counts_VBZ in_IN an_DT STI_NNP trial_NN in_IN chronic_JJ HIV-_NNP 1_CD infection_NN [_NN 62_CD ]_NN ._. These_DT additional_JJ therapeutic_JJ
        interventions_NNS deserve_VBP further_JJ investigation_NN in_IN future_JJ STI_NNP studies_NNS ._.
        Although_IN the_DT present_JJ study_NN shows_VBZ progressive_JJ viral_JJ breakthrough_NN ,_, it_PRP was_VBD not_RB designed_VBN to_TO
        address_VB whether_IN there_EX might_MD be_VB a_DT change_NN in_IN set_VBN point_NN viremia_NN achieved_VBN or_CC overall_JJ clinical_JJ
        benefit_NN through_IN transient_JJ early_JJ treatment_NN of_IN acute_JJ HIV_NNP infection_NN ._. The_DT definition_NN of_IN failure_NN
        chosen_VBN for_IN this_DT study_NN was_VBD a_DT viral_JJ load_NN of_IN greater_JJR than_IN 5_CD ,_, 000_CD RNA_NNP copies_NNS /_NN ml_NN plasma_NN ,_, which_WDT at_IN
        the_DT time_NN the_DT study_NN was_VBD initiated_VBN corresponded_VBD to_TO the_DT level_NN of_IN viremia_NN at_IN which_WDT treatment_NN
        was_VBD recommended_VBN ._. Larger_NNP randomized_JJ trials_NNS will_MD be_VB needed_VBN to_TO determine_VB the_DT potential_JJ
        clinical_JJ and_CC virologic_JJ benefit_NN of_IN approaches_NNS based_VBN on_IN STIs_NNP ._. In_IN studies_NNS of_IN untreated_JJ
        infection_NN ,_, there_EX is_VBZ only_RB a_DT 5_CD -_: fold_VB difference_NN in_IN viremia_NN separating_VBG the_DT quartile_NN with_IN the_DT
        slowest_JJS disease_NN progression_NN from_IN the_DT quartile_NN with_IN the_DT most_RBS rapid_JJ progression_NN [_NN 63_CD ]_NN ,_,
        suggesting_VBG that_IN small_JJ differences_NNS in_IN steady-state_JJ viremia_NN may_MD influence_VB clinical_JJ outcome_NN ._.
        In_IN the_DT meantime_NN ,_, STI_NNP probably_RB should_MD be_VB avoided_VBN outside_IN the_DT setting_NN of_IN controlled_VBN clinical_JJ
        trials_NNS ._. The_DT data_NNS in_IN this_DT study_NN may_MD also_RB be_VB relevant_JJ to_TO current_JJ efforts_NNS to_TO develop_VB a_DT
        therapeutic_JJ AIDS_NNP vaccine_NN designed_VBN to_TO retard_VB disease_NN progression_NN rather_RB than_IN prevent_VB
        infection_NN ,_, since_IN they_PRP suggest_VBP that_IN durable_JJ maintenance_NN of_IN low-level_JJ viremia_NN may_MD be_VB
        difficult_JJ to_TO achieve_VB ._.
      
      
        Supporting_VBG Information_NNP
      
    
  
